Previous Close | 11.24 |
Open | 11.48 |
Bid | 11.38 x 1000 |
Ask | 11.45 x 300 |
Day's Range | 11.28 - 11.50 |
52 Week Range | 8.24 - 13.24 |
Volume | |
Avg. Volume | 7,057,513 |
Market Cap | 9.179B |
Beta (5Y Monthly) | 1.34 |
PE Ratio (TTM) | 2.16 |
EPS (TTM) | 5.27 |
Earnings Date | Jun 26, 2024 - Jul 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.90 |
Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their...
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.